- Trials with a EudraCT protocol (17)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
17 result(s) found for: Gallbladder drainage.
Displaying page 1 of 1.
EudraCT Number: 2018-003707-19 | Sponsor Protocol Number: MS200647_0047 | Start Date*: 2019-04-15 | ||||||||||||||||||||||||||
Sponsor Name:Merck KGaA | ||||||||||||||||||||||||||||
Full Title: A Phase II, Multicenter, Open label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or are Intolera... | ||||||||||||||||||||||||||||
Medical condition: Biliary Tract Cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) IT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-003709-33 | Sponsor Protocol Number: AIO-HEP-0116 | Start Date*: 2017-05-04 | |||||||||||||||||||||||||||||||
Sponsor Name:AIO-Studien-gGmbH | |||||||||||||||||||||||||||||||||
Full Title: A randomized phase II trial of nal-IRI and 5-Fluorouracil compared to 5-Fluorouracil in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies | |||||||||||||||||||||||||||||||||
Medical condition: advanced, unresectable and metastatic cholangio- and gallbladder carcinoma | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005850-22 | Sponsor Protocol Number: 62202-788 | Start Date*: 2008-07-28 | |||||||||||
Sponsor Name:BGDO | |||||||||||||
Full Title: GEMCITABINE AND CETUXIMAB IN PATIENTS WITH ADVANCED OR METASTATIC BILIARY TRACT CANCER: A BGDO MULTICENTER PHASE II STUDY | |||||||||||||
Medical condition: Patients with advanced biliary tract cancer, excluding gallbladder cancer, where surgery is not feasible. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001025-28 | Sponsor Protocol Number: NuTide:121 | Start Date*: 2019-06-06 |
Sponsor Name:NuCana plc | ||
Full Title: A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary T... | ||
Medical condition: Histologically- or cytologically-confirmed adenocarcinoma of the biliary tract (including gallbladder, intra and extra-hepatic biliary ducts and ampullary cancers) that is locally advanced, unresec... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-003242-28 | Sponsor Protocol Number: D4280C00015 | Start Date*: 2015-05-20 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A single blind, randomised, multi-centre, active controlled, trial to evaluate safety, tolerability, pharmacokinetics and efficacy of ceftazidime and avibactam when given in combination with metron... | |||||||||||||
Medical condition: Complicated Intra-Abdominal Infection (cIAI) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Completed) CZ (Completed) GR (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002936-26 | Sponsor Protocol Number: 17-157 | Start Date*: 2019-11-28 |
Sponsor Name:Heinrich-Heine-University Düsseldorf | ||
Full Title: Efficacy and safety of Trifluridine/Tipiracil in combination with Irinotecan as a second line therapy in patients with Cholangiocarcinoma | ||
Medical condition: Patients with advanced, non resectable or metastatic cholangio- and gallbladder carcinoma after failure to respond to a previous gemcitabine treatment. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003773-34 | Sponsor Protocol Number: IT001-303 | Start Date*: 2018-11-23 |
Sponsor Name:Iterum Therapeutics International Limited | ||
Full Title: A prospective Phase 3, double-blind, multicenter, randomized study of the efficacy and safety of sulopenem followed by sulopenem etzadroxil with probenecid versus ertapenem followed by ciprofloxaci... | ||
Medical condition: Complicated intra-abdominal infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LV (Completed) HU (Completed) BG (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-005686-20 | Sponsor Protocol Number: 004 | Start Date*: 2012-08-20 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients ... | |||||||||||||
Medical condition: Patients with Complicated Intra-Abdominal Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Prematurely Ended) PT (Completed) GR (Completed) LT (Completed) LV (Completed) EE (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002726-39 | Sponsor Protocol Number: D4910C00009/C3601001 | Start Date*: 2016-02-25 |
Sponsor Name:Pfizer Inc. | ||
Full Title: A Phase IIa prospective, open-label, multicenter study to determine the pharmacokinetics (PK) and safety and tolerability of aztreonam-avibactam (ATM-AVI) for the treatment of complicated Intra-Abd... | ||
Medical condition: Complicated Intra-Abdominal Infections (cIAIs) in hospitalized adults | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-005604-54 | Sponsor Protocol Number: NXL104/2002 | Start Date*: 2009-04-10 | ||||||||||||||||
Sponsor Name:Novexel, S.A. | ||||||||||||||||||
Full Title: A prospective, multicentre, double-blind, randomized, comparative study to estimate the safety, tolerability and efficacy of NXL104/ceftazidime plus metronidazole vs. meropenem in the treatment of ... | ||||||||||||||||||
Medical condition: Complicated intra-abdominal infections (cIAI) in hospitalised adults | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001459-38 | Sponsor Protocol Number: KTP-004 | Start Date*: 2019-12-10 |
Sponsor Name:Karus Therapeutics Limited | ||
Full Title: A Phase II study of selective HDAC6 inhibition with KA2507 in advanced biliary tract cancer previously treated with standard of care chemotherapy (ABC-11) | ||
Medical condition: Advanced Biliary Tract Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001812-30 | Sponsor Protocol Number: CFTSp048 | Start Date*: 2013-10-23 | |||||||||||
Sponsor Name:The Christie NHS Foundation Trust | |||||||||||||
Full Title: A Phase III, randomised, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy for patients with locally advanced/metastatic biliary tract c... | |||||||||||||
Medical condition: Biliary tract cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004699-31 | Sponsor Protocol Number: I3O-MC-JSBF | Start Date*: 2016-03-23 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Gemcitabine and Cisplatin as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer | |||||||||||||
Medical condition: Advanced or Metastatic Biliary Tract Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) HU (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) SE (Completed) AT (Completed) CZ (Completed) ES (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003759-14 | Sponsor Protocol Number: GO42661 | Start Date*: 2021-01-21 | ||||||||||||||||
Sponsor Name:F. Hoffman-La Roche Ltd. | ||||||||||||||||||
Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT BEVACIZUMAB IN COMBINATION WITH CISPLATIN PLUS GEMCITABINE IN PATIENTS WITH UNTREATED, ADVANCED BILIAR... | ||||||||||||||||||
Medical condition: Biliary tract cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-000485-35 | Sponsor Protocol Number: LRS114689 | Start Date*: 2011-07-27 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
Full Title: Study LRS114689: A Study to Assess the Safety, Tolerability and Preliminary Efficacy of GSK2251052 in the treatment of complicated intra-abdominal infection in adults. | |||||||||||||
Medical condition: Intra-abdominal infections. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003638-18 | Sponsor Protocol Number: AG0112CR | Start Date*: 2013-03-13 |
Sponsor Name:Australasian Gastro-Intestinal Trials Group, Sydney University | ||
Full Title: Randomised Phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic CRC with either KRAS WT or G13D mutation. ICE CREAM: The Irinotecan Cetuximab Evaluation a... | ||
Medical condition: metastatic colorectal cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) IT (Completed) BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-003895-35 | Sponsor Protocol Number: D4280C00005 | Start Date*: 2012-04-11 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole V... | |||||||||||||
Medical condition: Complicated Intra-Abdominal Infection (cIAI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) CZ (Completed) GR (Completed) ES (Completed) BG (Completed) IT (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
